<SEC-DOCUMENT>0001157523-22-000396.txt : 20220406
<SEC-HEADER>0001157523-22-000396.hdr.sgml : 20220406
<ACCEPTANCE-DATETIME>20220406083043
ACCESSION NUMBER:		0001157523-22-000396
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220406
FILED AS OF DATE:		20220406
DATE AS OF CHANGE:		20220406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FSD Pharma Inc.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		22809454

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 4000
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52655865.htm
<DESCRIPTION>FSD PHARMA INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif; font-size: 16pt;">
      <div style="text-align: center; font-weight: bold;">Form 6-K</div>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">For the month of: <font style="font-weight: bold;"><u>April 2022</u></font></div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Commission File Number: <font style="font-weight: bold;"><u>001-39152</u></font></div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FSD PHARMA INC.</div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(Translation of registrant&#8217;s name into English)</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">199 Bay St., Suite 4000</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Toronto, Ontario M5L 1A9, Canada</div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">(Address of principal executive office)</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif;">Form 20-F&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</font></div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SIGNATURES</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; font-family: 'Times New Roman',Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.</div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <table cellspacing="0" cellpadding="0" border="0" id="zf6a1ea09aa1f48d8b50cd5f2934a0e5a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="width: 3%;">
              <div>FSD Pharma Inc.</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1" style="width: 3%;">
              <div>(Registrant)</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 42%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 42%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; font-family: 'Times New Roman',Times,serif; text-align: left;">Date:&#160; April 6, 2022</td>
            <td style="width: 3%; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 42%; border-bottom: 2px solid rgb(0, 0, 0); text-align: left; vertical-align: bottom;">
              <div>/s/ Nathan Coyle</div>
            </td>
            <td style="width: 5%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 3%;">
              <div>&#160;</div>
            </td>
            <td style="width: 42%;">
              <div>
                <div>
                  <div style="font-family: 'Times New Roman',Times,serif;">Nathan Coyle, Chief Financial Officer</div>
                </div>
              </div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center;"> <font style="font-weight: bold;">EXHIBIT INDEX</font><br>
    </div>
    <div><br>
    </div>
    <br>
    <table cellspacing="0" cellpadding="0" border="0" id="z104931e93e66499f8c46a0f416525d54" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 10%;">
            <div><font style="font-weight: bold;"><u>Exhibit</u></font><br>
            </div>
          </td>
          <td style="width: 90%; font-weight: bold;">
            <div><u>Description</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%;">
            <div>&#160;</div>
          </td>
          <td style="width: 90%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%;">
            <div><a href="a52655865ex99_1.htm">99.1</a></div>
          </td>
          <td style="width: 90%;">
            <div><a href="a52655865ex99_1.htm">Press Release &#8211; Dated April 6, 2022<br>
              </a> </div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52655865ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: businesswire
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>FSD Pharma Issues Corporate Updates</b> </h1>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>TORONTO--(BUSINESS WIRE)--April 6, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (&#8220;<b>FSD Pharma</b>&#8221; or the &#8220;<b>Company</b>&#8221;), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions,
            announced today the following corporate updates; </p>
          <p> 1. FSD Pharma adds industry leaders Jason Sawyer and Dr. Ravinder Kumar to its Advisory Board. </p>
          <p style="margin-left: 30px;"> Jason Sawyer brings 29 years of alternative investment and business experience to FSD&#8217;s drug development efforts. He currently serves as the General Manager of Access Alternative Group S.A. (&#8220;AAG&#8221;), a Bahamas-based
            boutique venture investment and advisory firm. Prior to his role at AAG, Sawyer was a Principal at Crane Capital Associates and Head of its Absolute Return Strategies Group where he successfully raised more than $3.5 billion for some of the
            world's leading private equity and hedge funds. In 2016, he founded Pacific West Stone and led the capital formation, investing $4.5MM in its first-year start-up phase and securing private equity financing backed by one of Canada&#8217;s largest
            pension funds. </p>
          <p style="margin-left: 30px;"> Rav Kumar, PhD is an award-winning pharmaceutical industry leader, with over 30 years of global experience developing and commercializing novel drug solutions. Through his advisory role, Dr. Kumar will contribute
            his expertise in discovery, regulatory, preclinical and clinical, product development, manufacturing, compliance and commercialization. Dr. Kumar is currently the Director of the Centre for Medicinal Chemistry at the University of Toronto, and
            Chief Strategy Officer at Dalriada Drug Discovery. Prior to his current roles, Dr. Kumar served as Chief Science Officer and Advisor to The Green Organic Dutchman, Managing Director of Apotex India, and Vice President of R&amp;D Operations,
            Business Development &amp; Classic Brands at GlaxoSmithKline Canada. </p>
          <p> 2. FSD Pharma has been expanding its team aggressively at all levels to synergize its operations. The company adds the following employees to the team: Dr. Andrzej Chruscinski (Associate Vice-President, Clinical Affairs), Mr. Kevin Cassidy
            (Vice-President, Quality Systems), and Dr. Oksana Akhova (Director, Licensing, Partnership and IP). </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p style="margin-left: 30px;"> Dr. Andrzej Chruscinski trained as a physician-scientist at Stanford University earning an MD/PhD. While at Stanford, he also completed training Internal Medicine and Cardiology. After moving to Toronto, he
            completed a fellowship in Advanced Heart Failure/Transplantation at University Health Network. As a scientist at University Health Network, he ran a research group investigating mechanisms of transplantation tolerance. He developed antigen
            microarray technology to profile autoantibodies to monitor allograft function. More recently, he completed two clinical trials of tolerance induction in solid organ transplantation (LITMUS and ASCOTT). Dr. Chruscinski currently holds a medical
            license in Michigan, USA. </p>
          <p style="margin-left: 30px;"> Mr. Kevin Cassidy brings over 39 years of biotechnology experience to FSD Pharma. He has established and run operations, validated facilities for GMP manufacturing, biotherapeutic development, and quality testing in
            Canada, Chile and China. He was lead on process and business development, resulting in the first approved adenovirus-vectored vaccine. The rabies vaccine is the predecessor to several vaccines deployed in the COVID-19 pandemic. Mr. Cassidy was
            trained in Business Management at George Brown College and received a Bachelor of Science degree from University of Toronto. </p>
          <p style="margin-left: 30px;"> Dr. Oksana Akhova has over two decades of experience both in industry and academia in business development, IP management and commercialization of innovative technologies. She worked across in a range of roles in
            academia and industry and she has strong track record in commercial licensing, management of private-public partnerships, technology marketing and business development. She has solid expertise in evaluation of companies and technologies in
            oncology, ophthalmology, inflammation and neurology, building financial models and IP management. She holds a PhD in oncology and an MBA with specialization in biotechnology management. </p>
          <p> 3. FSD Pharma returns to treasury 1,524,700 shares as of 31 March through its buyback program. </p>
          <p> 4. FSD Pharma adopts the RSU program and issues RSUs in Lieu of options held by Directors and Senior Management. </p>
          <p> <b>About FSD Pharma</b> </p>
          <p> FSD Pharma Inc. is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences, Inc. (&#8220;<b>FSD BioSciences</b>&#8221;), a wholly owned subsidiary, is focused on pharmaceutical research and development of
            its lead compound, ultra-micronized palmitoyl ethylamine (&#8220;<b>PEA</b>&#8221;) or FSD-PEA (formerly called FSD-201). Lucid Psycheceuticals Inc. (&#8220;<b>Lucid</b>&#8221;), a wholly owned subsidiary, is focused on the research and development of its lead
            compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the
            potential treatment of neurodegenerative disorders. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Company: <br>
            Zeeshan Saeed, Founder, President and Executive Co-Chairman of the Board, FSD Pharma Inc. <br>
            Email: Zsaeed@fsdpharma.com<br>
            Telephone: (416) 854-8884 </p>
          <p> Investor Relations: <br>
            Email: ir@fsdpharma.com, info@fsdpharma.com<br>
            Website: www.fsdpharma.com </p>
          <p> Media Relations: <br>
            KCSA Strategic Communications <br>
            Email: FSDPharma@KCSA.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
